MOXR 0916

Drug Profile

MOXR 0916

Alternative Names: MOXR0916; RG 7888

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Apr 2016 Preliminary efficacy, safety and pharmacokinetics data from a phase I trial in Solid tumours was presented at the 107th Annual Meeting of the American Association for Cancer Research
  • 07 Apr 2015 Genentech plans a phase I trial for Solid tumours (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT02410512)
  • 01 Aug 2014 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top